Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of temozolomide population pharmacokinetics, efficacy and safety in glioma
ChiCTR2100053394Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of temozolomide in glioma, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Population pharmacokinetic model of temozolomide. Started Jun 2021; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2100053394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053394.